Study Finds No Benefit to Pausing Arthritis Drugs Before COVID Vaccination

A randomized trial of 840 arthritis patients found that temporarily stopping targeted immunosuppressant drugs before COVID-19 vaccination did not improve antibody responses compared to continuing the medications. Patients who paused their disease-modifying antirheumatic drugs had more than double the odds of experiencing an arthritis flare during follow-up. The findings suggest that patients with inflammatory arthritis can safely receive COVID-19 vaccines without interrupting their treatment regimens.

The trial enrolled arthritis patients taking various immunosuppressive medications, including TNF inhibitors, JAK inhibitors, interleukin-17 inhibitors, and T-cell activation blockers. These drugs work by dampening the immune system to control inflammatory arthritis symptoms, raising theoretical concerns that they might also reduce vaccine effectiveness. The research team measured antibody production six weeks after vaccination as their primary indicator of immune response, while also tracking whether disease flares occurred in both groups during the follow-up period.

The findings challenge pandemic-era guidance that suggested temporarily discontinuing these medications might enhance vaccine protection. By quantifying both immune response and disease outcomes, the study demonstrates that the risks of pausing treatment—particularly increased arthritis flares—outweigh any theoretical immunological gains from the interruption.